Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.

Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, DiazGranados C, Landolfi V.

Vaccine. 2014 May 1;32(21):2507-17. doi: 10.1016/j.vaccine.2013.09.074. Epub 2013 Oct 11.

PMID:
24120672
[PubMed - in process]
Free Article
2.

Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.

Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH.

Vaccine. 2013 May 1;31(19):2358-65. doi: 10.1016/j.vaccine.2013.03.008. Epub 2013 Mar 13.

PMID:
23499604
[PubMed - indexed for MEDLINE]
3.

Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.

Frenck RW Jr, Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, Hay CM, Dekker CL, Walter EB Jr, Cate TR, Edwards KM, Hill H, Wolff M, Leduc T, Tornieporth N.

Vaccine. 2011 Aug 5;29(34):5666-74. doi: 10.1016/j.vaccine.2011.06.010. Epub 2011 Jun 23.

PMID:
21699951
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.

Gorse GJ, Falsey AR, Johnson CM, Morrison D, Fried DL, Ervin JE, Greenberg DP, Ozol-Godfrey A, Landolfi V, Tsang PH.

Vaccine. 2013 Dec 5;31(50):6034-40. doi: 10.1016/j.vaccine.2013.09.012. Epub 2013 Sep 20.

PMID:
24055306
[PubMed - indexed for MEDLINE]
5.

A dose-range study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.

Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli G, Groth N, Levin Y, Del Giudice G.

Hum Vaccin Immunother. 2014 Apr 14;10(6). [Epub ahead of print]

PMID:
24732325
[PubMed - as supplied by publisher]
6.

Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.

Hung IF, Levin Y, To KK, Chan KH, Zhang AJ, Li P, Li C, Xu T, Wong TY, Yuen KY.

Vaccine. 2012 Oct 5;30(45):6427-35. doi: 10.1016/j.vaccine.2012.08.014. Epub 2012 Aug 18.

PMID:
22910287
[PubMed - indexed for MEDLINE]
7.

Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.

Chi RC, Rock MT, Neuzil KM.

Clin Infect Dis. 2010 May 15;50(10):1331-8. doi: 10.1086/652144.

PMID:
20377407
[PubMed - indexed for MEDLINE]
Free Article
8.

Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.

Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ.

J Infect Dis. 2009 Jul 15;200(2):172-80. doi: 10.1086/599790.

PMID:
19508159
[PubMed - indexed for MEDLINE]
Free Article
9.

Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.

Ansaldi F, Valle L, de Florentiis D, Parodi V, Murdaca G, Bruzzone B, Durando P, Setti M, Icardi G.

Hum Vaccin Immunother. 2012 Aug;8(8):1048-52. doi: 10.4161/hv.20347. Epub 2012 Aug 1.

PMID:
22832261
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Immunogenicity and safety of Intanza(®)/IDflu(®) intradermal influenza vaccine in South Korean adults: a multicenter, randomized trial.

Hoon Han S, Hee Woo J, Weber F, Joo Kim W, Ran Peck K, Il Kim S, Hwa Choi Y, Myung Kim J.

Hum Vaccin Immunother. 2013 Sep;9(9):1971-7. doi: 10.4161/hv.25295. Epub 2013 Jun 18.

PMID:
23778938
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.

Ansaldi F, Canepa P, Ceravolo A, Valle L, de Florentiis D, Oomen R, Vogel FR, Denis M, Samson SI, Icardi G.

Vaccine. 2012 Apr 16;30(18):2908-13. doi: 10.1016/j.vaccine.2012.02.003. Epub 2012 Feb 15.

PMID:
22342501
[PubMed - indexed for MEDLINE]
12.

A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events.

Marra F, Young F, Richardson K, Marra CA.

Influenza Other Respir Viruses. 2013 Jul;7(4):584-603. doi: 10.1111/irv.12000. Epub 2012 Sep 13. Review.

PMID:
22974174
[PubMed - indexed for MEDLINE]
13.

Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.

Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y.

Vaccine. 2009 Jan 14;27(3):454-9. doi: 10.1016/j.vaccine.2008.10.077. Epub 2008 Nov 18.

PMID:
19022318
[PubMed - indexed for MEDLINE]
14.

High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season.

DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK.

Vaccine. 2013 Jan 30;31(6):861-6. doi: 10.1016/j.vaccine.2012.12.013. Epub 2012 Dec 20.

PMID:
23261045
[PubMed - indexed for MEDLINE]
15.

Dose sparing with intradermal injection of influenza vaccine.

Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM.

N Engl J Med. 2004 Nov 25;351(22):2295-301. Epub 2004 Nov 3.

PMID:
15525714
[PubMed - indexed for MEDLINE]
Free Article
16.

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.

Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.

Vaccine. 2013 Jan 21;31(5):770-6. doi: 10.1016/j.vaccine.2012.11.074. Epub 2012 Dec 8.

PMID:
23228813
[PubMed - indexed for MEDLINE]
17.

Nine µg intradermal influenza vaccine and 15 µg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults.

Nolwenn N, Bisceglia H, Rozières A, Goujon C, Boudet F, Laurent P, Vanbervliet B, Rodet K, Hennino A, Nicolas JF.

Hum Vaccin Immunother. 2014 Jul 3;10(9). [Epub ahead of print]

PMID:
25003750
[PubMed - as supplied by publisher]
18.

Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.

Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, Reisinger EC.

PLoS One. 2013 Aug 16;8(8):e70866. doi: 10.1371/journal.pone.0070866. eCollection 2013.

PMID:
23976960
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

The immunogenicity of intradermal influenza vaccination in COPD patients.

Chuaychoo B, Wongsurakiat P, Nana A, Kositanont U, Maranetra KN.

Vaccine. 2010 May 28;28(24):4045-51. doi: 10.1016/j.vaccine.2010.04.006. Epub 2010 Apr 20.

PMID:
20412877
[PubMed - indexed for MEDLINE]
20.

Immunogenicity and safety of intradermal influenza vaccine in children.

Esposito S, Daleno C, Picciolli I, Tagliaferri L, Scala A, Prunotto G, Montinaro V, Galeone C, Principi N.

Vaccine. 2011 Oct 13;29(44):7606-10. doi: 10.1016/j.vaccine.2011.08.021. Epub 2011 Aug 17.

PMID:
21855592
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk